


IN THE CLAIMS

Please amend the claims as follows:

1. (Previously Presented) A phenylpyridazine derivative represented by the formula (1):



wherein:

R¹ is optionally substituted or unsubstituted C₁-C₁₂ alkyl, or substituted or unsubstituted C₂-C₁₂ alkenyl; wherein the alkyl can be linear, branched, cyclic or a structure containing a cyclic structure therein,

wherein, if substituted, the substituent on the alkyl or alkenyl represented by R¹ is independently a substituted or unsubstituted C₆-C₁₄ aryl or a 5- or 6-membered heteroaryl having 1 to 3 nitrogen atoms; and said aryl or heteroaryl, wherein if substituted, the aryl or heteroaryl are substituted with 1 to 3 substituents selected from the group consisting of halogen, C₁-C₁₂ alkyl, C₁-C₁₂ alkoxy, and combinations thereof;

R^2 and R^3 each independently represents hydrogen or C_1 - C_{12} alkyl, hydroxy C_1 - C_{12} alkyl, dihydroxy C_1 - C_{12} alkyl or C_3 - C_{12} alkynyl, or R^2 and R^3 are fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated 5- to 7- membered heterocyclic group;

wherein, if substituted, the 5-to 7-membered heterocyclic group is substituted with at least one of a halogen atom, C_1 - C_{12} alkyl, C_1 - C_{12} alkoxycarbonyl or phenyl- C_1 - C_7 alkyl,

X, Y and Z each independently represents hydrogen, ~~or~~ halogen, substituted or unsubstituted C_1 - C_{12} alkyl, C_1 - C_{12} alkoxy, C_1 - C_{12} alkylthio, C_1 - C_{12} alkylsulfinyl, ~~or~~ C_1 - C_{12} alkylsulfonyl, or C_6 - C_{14} aryl;

wherein the C_1 - C_{12} alkyl is optionally substituted with at least one of a halogen atom or C_1 - C_{12} alkoxy, the aryl is optionally substituted with at least one of a halogen, C_1 - C_{12} alkyl, or C_1 - C_{12} alkoxy; and

n stands for a number of from 1 to 5;

with the proviso that R^2 and R^3 are not hydrogens or the same C_1 - C_3 alkyl groups at the same time when R^1 is a benzyl group or a C_1 - C_3 alkyl group; or a salt thereof.

Claims 2-7 (Cancelled).

8. (Original) The compound of Claim 1, wherein R^1 is a group selected from halogenobenzyl, dihalogenobenzyl, (halogenophenyl)ethyl, (dihalogenophenyl)ethyl, (halogenophenyl)propyl or (dihalogenophenyl)propyl; $R^2(R^3)N-$ is a group selected from amino, dimethylamino, piperazinyl or N-methylpiperazinyl; X is halogen or methoxy; Y is methyl or halogen; Z is hydrogen; and n stands for 1 or 3.

9. (Original) The compound of Claim 1, wherein R^1 is a group selected from chlorobenzyl, dichlorobenzyl, fluorobenzyl, difluorobenzyl, (chlorophenyl)ethyl, (dichlorophenyl)ethyl, (chlorophenyl)propyl or (dichlorophenyl)propyl; $R^2(R^3)N-$ is a group selected from amino, dimethylamino, piperazinyl or N-methylpiperazinyl; X is halogen or methoxy; Y is methyl or halogen; Z is hydrogen; and n stands for 1 or 3.

Claims 10-12 (Cancelled).

Claims 13-17 (Cancelled).


18. (Previously Presented) A pharmaceutical composition comprising the compound of claim 1 or a salt thereof and a pharmacologically acceptable carrier.

Claims 19-23 (Cancelled)

24 (Currently Amended) ~~The method of claim 23, wherein the disease is immune system diseases, inflammatory diseases, ischemic diseases,~~ A method of treating osteoporosis[.,.] or ichorrhemia in an individual comprising administering the compound of claim 1 or a salt thereof in an amount sufficient to treat osteoporosis or ichorrhemia in the individual.

25. (Currently Amended) ~~The method of claim 23, wherein the disease is A~~
method of treating rheumatism, arthritis or inflammatory colitis in an individual
comprising, administering the compound of claim 1 or a salt thereof in an amount
sufficient to treat osteoporosis or ichorrhemia in the individual.

26. (Previously Presented) A phenylpyridazine derivative represented by the
formula (1):



wherein:

R¹ is optionally substituted or unsubstituted C₁-C₇ alkyl, or substituted or unsubstituted C₂-C₇ alkenyl; wherein the alkyl can be linear, branched, cyclic or a structure containing a cyclic structure therein,

wherein, if substituted, the substituent on the alkyl or alkenyl represented by R¹ is phenyl, which is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, C₁-C₇ alkyl, C₁-C₇ alkoxy, and combinations thereof;

R^2 and R^3 each independently represents hydrogen or C_1 - C_7 alkyl or R^2 and R^3 are fused together with the adjacent nitrogen atom to form a piperazinyl, wherein the piperazinyl is optionally substituted with one or more of an alkyl or a hydroxyl- C_1 - C_7 -alkyl;

X, Y and Z each independently represents hydrogen, halogen, C_1 - C_7 alkyl, or C_1 - C_7 alkoxy; and

n stands for a number of from 1 to 5;

with the proviso that R^2 and R^3 are not hydrogens or the same C_1 - C_3 alkyl groups at the same time when R^1 is a benzyl group or a C_1 - C_3 alkyl group; or a salt thereof.

27. (Previously Presented) A pharmaceutical composition comprising the compound of claim 26 or a salt thereof and a pharmacologically acceptable carrier.

Claim 28 (Cancelled).

29 (Currently Amended) ~~The method of claim 28, wherein the disease is immune system diseases, inflammatory diseases, ischemic diseases,~~ A method of treating osteoporosis, or ichorrhemia in an individual comprising, administering the compound of claim 26 or a salt thereof in an amount sufficient to treat osteoporosis or ichorrhemia in the individual.

30. (Currently Amended) ~~The method of claim 28, wherein the disease is A~~ method of treating rheumatism, arthritis or inflammatory colitis in an individual

Application No. 10/544,881

Reply to Office Action of October 25, 2006

comprising, administering the compound of claim 26 or a salt thereof in an amount sufficient to treat osteoporosis or ichorrhemia in the individual.